Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00024180 · ClinicalTrials.gov registry record · Phase 1
FR901228 in Treating Patients With Hematologic Cancer
A Phase 1 study, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00024180: Completed Phase 1 study, sponsored by Ohio State University Comprehensive Cancer Center.
NCT00024180 is a Phase 1 study that has completed, run by Ohio State University Comprehensive Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00024180, a Phase 1 study, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of FR901228 in treating patients who have hematologic cancer.
Interventions
- DRUG romidepsin
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-01 |
| Est. Completion | 2006-08 |
| Phase | Phase 1 |
What the finished NCT00024180 record still lists
NCT00024180 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which romidepsin is the first listed.
NCT00024180 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00024180 about?
NCT00024180 is a clinical study titled "FR901228 in Treating Patients With Hematologic Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of FR901228 in treating patients who have hematologic cancer.
What is the current status of trial NCT00024180?
This trial is currently completed. It is a Phase 1 study. The study started on 2002-01. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00024180?
The interventions under investigation include: romidepsin (DRUG).
Who is sponsoring clinical trial NCT00024180?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia